About this trial
To determine if vascular beta3 adrenergic receptors are present and functional in aging women and can be targeted to attenuate sympathetic vasoconstriction and enhance vascular function in aging women.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Healthy women,
Assigned female at birth,
18-70 years of age,
Body mass index <18 or ≥30 kg/m2,
Disqualifiers
Assigned male at birth,
Pregnancy,
Breastfeeding,
History of hormone replacement therapy, chemical menopause, or oophor-ectomy
Trial design
Design model
Crossover
Treatments tested in this trial
Placebo
DrugParticipants will receive a placebo in pill form.
Gemtesa
DrugParticipants will receive oral gemtesa (75 mg).
Treatment groups
60 Participants
are divided into 2 treatment groupsGroup A: Cold pressor testExperimental treatment 2 interventions
Group B: Flow Mediated DilationExperimental treatment 2 interventions
Trial outcomes
Primary outcomes
1
Blood flow
Blood flow measured with Doppler ultrasound.
Time frame
Change from baseline to minute 2.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov